Pixium Vision SA represents a strong commitment to innovation and improving the lives of visually impaired individuals. The company focuses on developing innovative and breakthrough visual prosthetic systems, such as its flagship product, the Prima System. Pixium Vision SA aims to restore sight and enable greater independence for individuals with retinal dystrophies. With a patient-centered approach, the company emphasizes collaboration with healthcare professionals and strives to provide personalized solutions. Guided by a corporate philosophy rooted in research and development, Pixium Vision SA is dedicated to pushing the boundaries of vision restoration technology to enhance the quality of life for those affected by vision loss.

Pixium Vision SA is primarily present in France and Europe.

Pixium Vision SA has achieved several significant milestones. Firstly, the company successfully developed and launched its innovative retinal implant technology, the PRIMA System. This breakthrough product aims to restore vision for patients suffering from retinal dystrophies. In addition, Pixium Vision SA has made substantial progress in clinical trials, demonstrating the effectiveness and safety of their implants. The company has also obtained important regulatory approvals, including the European CE mark, further validating its cutting-edge technology. Furthermore, Pixium Vision SA has secured strategic partnerships, collaborations, and funding, enabling them to continue their research and development efforts. These achievements highlight Pixium Vision SA's commitment to advancing vision restoration and establishing itself as a leader in the field.

Pixium Vision SA is a leading company in the field of advanced retinal implants. Founded in 2011, Pixium Vision is dedicated to developing innovative solutions for patients suffering from vision loss. The company has a strong focus on research and development, working closely with leading experts in ophthalmology and vision science. Pixium Vision aims to provide cutting-edge technologies that restore partial vision to those affected by retinal degenerative diseases. With a commitment to improving the quality of life for visually impaired individuals, Pixium Vision continues to push the boundaries of retinal implant technology, making significant advancements in the field.

The main competitors of Pixium Vision SA in the market include companies like Second Sight Medical Products, Inc. and Retina Implant AG. These companies also specialize in developing and manufacturing innovative visual prostheses and implantable devices for the treatment of blindness or severe vision impairment. Pixium Vision SA competes with these companies in terms of technological advancements, product quality, market share, and research and development efforts. However, it is important to note that competition may vary depending on specific geographic regions and the niche markets that these companies target.

Pixium Vision SA is primarily active in the medical device industry, specifically in the field of ophthalmology. As a leading company in vision restoration, Pixium Vision specializes in developing innovative bionic vision systems. These systems aim to restore sight for individuals affected by retinal dystrophies or age-related macular degeneration. By harnessing advanced technology and expert knowledge, Pixium Vision is dedicated to providing cutting-edge solutions that improve the quality of life for visually impaired individuals. With a strong presence in the healthcare sector, Pixium Vision showcases its commitment to advancing ophthalmic care and enhancing visual perception.

Pixium Vision SA's business model centers around developing and commercializing innovative bionic vision systems. The company specializes in creating solutions for individuals with severe vision impairment or blindness. Pixium Vision SA's advanced technology focuses on designing retinal implants that stimulate the remaining functional cells and provide artificial vision to patients. By combining expertise in bioengineering, electronics, and artificial intelligence, the company aims to improve the quality of life for visually impaired individuals. With a strong commitment to research and development, Pixium Vision SA strives to revolutionize the field of vision restoration.

Poměr Pixium Vision P/E je -0,02.

Koeficient Pixium Vision tržních hodnot je 0,45.

AlleAktien kvalitní skóre pro Pixium Vision je 3/10.

očekávané Pixium Vision obrat je 824 000,00 EUR.

očekávané Pixium Vision zisk je -18,90 mil. EUR.

Pixium Vision SA is a French company founded in 2011. The company develops innovative eye implants that can be used to treat visual impairments and blindness. The business model of Pixium Vision SA is based on the development and manufacturing of implants that can restore or improve vision. The company works closely with leading scientists and medical institutions to constantly research and develop new technologies. Pixium Vision SA uses two technology platforms: the Prima platform and the Iris-II platform. The Prima platform is a miniaturized image processing technology that allows images to be projected onto the retina to treat visual impairments. The Iris-II platform, on the other hand, is a complete artificial retina that can be used as a replacement for natural vision. Overall, Pixium Vision SA offers two products: the Prima implant for the treatment of macular degeneration and the Iris-II implant for the treatment of retinitis pigmentosa. The Prima implant consists of a small, implantable device that is inserted into the eye and contains a microdisplay that can project images directly onto the retina. The Prima implant is currently being tested in a clinical study with patients with advanced dry age-related macular degeneration (dry-AMD). The Iris-II implant, on the other hand, is an artificial retina consisting of a matrix of electrically stimulable pixels. The device is used to treat retinitis pigmentosa, an inherited eye disease that can lead to vision loss. The Iris-II implant is currently in the development phase and clinical trials. In addition to developing implants, Pixium Vision SA also provides consulting services in the field of medical technology. The company works closely with doctors and medical institutions to ensure that the implants are properly implanted and used. The business model of Pixium Vision SA is based on the development and manufacturing of innovative eye implants that can treat visual impairments and blindness. The company relies on close collaboration with scientists and medical institutions to constantly research and develop new technologies. With its products, the Prima implant and the Iris-II implant, Pixium Vision SA offers patients worldwide innovative treatment options.

Pixium Vision vyplácí dividendu ve výši 0 EUR rozdělenou do výplat během roku.

Dividenda pro Pixium Vision momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Pixium Vision je FR0011950641.

WKN společnosti Pixium Vision je A116CC.

Ticker společnosti Pixium Vision je ALPIX.PA.

Během posledních 12 měsíců vyplatila společnost Pixium Vision dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Pixium Vision vyplatí dividendu ve výši 0 EUR.

Výnos z dividend společnosti Pixium Vision aktuálně činí .

Pixium Vision vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Pixium Vision vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 EUR. To odpovídá dividendovému výnosu 0 %.

Pixium Vision je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Pixium Vision ve výši 0 EUR, zaznamenané 11. 9. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 11. 9. 2024.

Poslední dividendy byly vyplaceny dne 11. 9. 2024.

V roce 2023 společností Pixium Vision bylo vyplaceno 0 EUR ve formě dividend.

Dividendy společnosti Pixium Vision jsou vypláceny v EUR.